AAAAAA
Results:
1-11
|
Results: 11
Authors:
DEJONG R
ALTARE F
HAAGEN IA
ELFERINK DG
DEBOER T
VRIESMAN PJCV
KABEL PJ
DRAAISMA JMT
VANDISSEL JT
KROON FP
CASANOVA JL
OTTENHOFF THM
Citation: R. Dejong et al., SEVERE MYCOBACTERIAL AND SALMONELLA INFECTIONS IN INTERLEUKIN-12 RECEPTOR-DEFICIENT PATIENTS, Science, 280(5368), 1998, pp. 1435-1438
Authors:
SUZUKI S
KUMATORI A
HAAGEN IA
FUJII Y
SADAT MA
JUN HL
TSUJI Y
ROOS D
NAKAMURA M
Citation: S. Suzuki et al., PU.1 AS AN ESSENTIAL ACTIVATOR FOR THE EXPRESSION OF GP91(PHOX) GENE IN HUMAN PERIPHERAL NEUTROPHILS, MONOCYTES, AND B-LYMPHOCYTES, Proceedings of the National Academy of Sciences of the United Statesof America, 95(11), 1998, pp. 6085-6090
Authors:
HAAGEN IA
Citation: Ia. Haagen, PERFORMANCE OF CD3XCD19 BISPECIFIC MONOCLONAL-ANTIBODIES IN B-CELL MALIGNANCY, Leukemia & lymphoma, 19(5-6), 1995, pp. 381-393
Authors:
DEGAST GC
HAAGEN IA
VANHOUTEN AA
KLEIN SC
DUITS AJ
DEWEGER RA
VROOM TM
CLARK MR
PHILLIPS J
VANDIJK AJG
DELAU WBM
BAST BJEG
Citation: Gc. Degast et al., CD8 T-CELL ACTIVATION AFTER INTRAVENOUS ADMINISTRATION OF CD3XCD19 BISPECIFIC ANTIBODY IN PATIENTS WITH NON-HODGKIN-LYMPHOMA, Cancer immunology and immunotherapy, 40(6), 1995, pp. 390-396
Authors:
HAAGEN IA
GEERARS AJG
CLARK MR
VANDEWINKEL JGJ
Citation: Ia. Haagen et al., INTERACTION OF HUMAN MONOCYTE FC-GAMMA RECEPTORS WITH RAT IGG2B - A NEW INDICATOR FOR THE FC-GAMMA-RIIA (R-H131) POLYMORPHISM, The Journal of immunology, 154(4), 1995, pp. 1852-1860
Authors:
HAAGEN IA
GEERARS AJG
DELAU WBM
BAST BJEG
DEGAST C
Citation: Ia. Haagen et al., THE EFFICACY OF CD3 X CD19 BISPECIFIC MONOCLONAL-ANTIBODY (BSAB) IN ACLONOGENIC-ASSAY - THE EFFECT OF REPEATED ADDITION OF BSAB AND INTERLEUKIN-2, Blood, 85(11), 1995, pp. 3208-3212
Authors:
HAAGEN IA
DELAU WBM
BAST BJEG
GEERARS AJG
CLARK MR
DEGAST BC
Citation: Ia. Haagen et al., UNPRIMED CD4-CELLS CAN BE RAPIDLY ACTIVATED BY A CD3-X-CD19 BISPECIFIC ANTIBODY TO PROLIFERATE AND BECOME CYTOTOXIC( AND CD8+ T), Cancer immunology and immunotherapy, 39(6), 1994, pp. 391-396
Authors:
HAAGEN IA
GEERARS AJ
DELAU WB
CLARK MR
VANDEGRIEND RJ
BAST BJ
DEGAST BC
Citation: Ia. Haagen et al., KILLING OF AUTOLOGOUS B-LINEAGE MALIGNANCY USING CD3 X CD19 BISPECIFIC MONOCLONAL-ANTIBODY IN END-STAGE LEUKEMIA AND LYMPHOMA, Blood, 84(2), 1994, pp. 556-563
Authors:
DEGAST GC
HAAGEN IA
GEERARS AJG
DELAU WBM
BAST BJAB
Citation: Gc. Degast et al., EFFICACY OF CD3XCD19 BISPECIFIC ANTIBODY IN A CLONOGENIC-ASSAY - REPEATED ADDITION OF BSAB AND IL-2 IS NECESSARY, Blood, 84(10), 1994, pp. 10000430-10000430
Authors:
VANHOUTEN AA
HAAGEN IA
CLARK M
GEERARS A
DELAU W
BAST EJEG
DEGAST GC
Citation: Aa. Vanhouten et al., FIRST RESULTS OF INTRAVENOUS APPLICATION OF BISPECIFIC ANTIBODY (CD3 CD19 SHR-1) TO PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES - A PHASE-1 STUDY/, Experimental hematology, 21(8), 1993, pp. 1120-1120
Authors:
VANHOUTEN AA
HAAGEN IA
CLARK M
GEERARS A
DELAU W
VROOM TM
BAST EJEG
DEGAST GC
Citation: Aa. Vanhouten et al., CYTOKINE RELEASE AFTER INTRAVENOUS ADMINISTRATION OF BISPECIFIC ANTIBODY (CD3 CD19, SHR-1) - A PHASE-I STUDY IN PATIENTS WITH CD19 POSITIVEB-CELL MALIGNANCIES/, Blood, 82(10), 1993, pp. 10000580-10000580
Risultati:
1-11
|